Adeno-associated virus serotypes 9 and rh10 mediate strong neuronal transduction of the dog brain

Gene Therapy

Volumn 21, Issue 1, 2014, Pages 28-36

  Swain, G P ^a   Prociuk, M ^a   Bagel, J H ^a   O'Donnell, P ^a   Berger, K ^a   Drobatz, K ^a   Gurda, B L ^a   Haskins, M E ^a   Sands, M S ^b   Vite, C H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AAV; animal model; canine; CNS

Indexed keywords

GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; RECOMBINANT ADENO ASSOCIATED VIRUS 9 VECTOR; RECOMBINANT ADENO ASSOCIATED VIRUS RH10 VECTOR; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CAPSULA INTERNA; CAUDATE NUCLEUS; CELL TYPE; CONTROLLED STUDY; FLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROTYPE; THALAMUS; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS; ANIMALIA; CANIS FAMILIARIS; MURINAE; PRIMATES;

ANIMALS; BRAIN; CAUDATE NUCLEUS; CEREBRAL CORTEX; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOGS; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INTERNAL CAPSULE; SEROTYPING; THALAMUS; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84891743727     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.54     Document Type: Article

References (57)

1. Haskins M, Giger U. Lysosomal storage diseases. In: Kaneko JJ, Harvey JW, Bruss ML (eds.) Clinical Biochemistry of Domestic Animals. 6th edn. Elsevier: Amsterdam, 2008, pp 731-750.
2. Awano T, Johnson GS, Wade CM, Katz ML, Johnson GC, Taylor JF et al. Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2009; 106: 2794-2799.
3. Kyostila K, Cizinauskas S, Seppala EH, Suhonen E, Jeserevics J, Sukura A et al. A SEL1L mutation links a canine progressive early-onset cerebellar ataxia to the endoplasmic reticulum-associated protein degradation (ERAD) machinery. PLoS Genet 2012; 8: e1002759.
4. Seppala EH, Jokinen TS, Fukata M, Fukata Y, Webster MT, Karlsson EK et al. LGI2 truncation causes a remitting focal epilepsy in dogs. PLoS Genet 2011; 7: e1002194.
5. Zeng R, Farias FH, Johnson GS, McKay SD, Schnabel RD, Decker JE et al. A truncated retrotransposon disrupts the GRM1 coding sequence in Coton de Tulear dogs with Bandera's neonatal ataxia. J Vet Intern Med 2011; 25: 267-272.
6. Hungs M, Fan J, Lin L, Lin X, Maki RA, Mignot E. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res 2001; 11: 531-539. (Pubitemid 32331550)
7. Chen X, Johnson GS, Schnabel RD, Taylor JF, Johnson GC, Parker HG et al. A neonatal encephalopathy with seizures in standard poodle dogs with a missense mutation in the canine ortholog of ATF2. Neurogenetics 2008; 9: 41-49.
8. Fyfe JC, Al-Tamimi RA, Liu J, Schaffer AA, Agarwala R, Henthorn PS. A novel mitofusin 2 mutation causes canine fetal-onset neuroaxonal dystrophy. Neurogenetics 2011; 12: 223-232.
9. Penderis J, Calvin J, Abramson C, Jakobs C, Pettitt L, Binns MM et al. L-2-hydroxyglutaric aciduria: characterisation of the molecular defect in a spontaneous canine model. J Med Genet 2007; 44: 334-340. (Pubitemid 46732628)
10. Vernau KM, Runstadler JA, Brown EA, Cameron JM, Huson HJ, Higgins RJ et al. Genome-wide association analysis identifies a mutation in the thiamine transporter 2 (SLC19A3) gene associated with Alaskan Husky encephalopathy. PLoS One 2013; 8: e57195.
11. Forman OP, De Risio L, Stewart J, Mellersh CS, Beltran E. Genome-wide mRNA sequencing of a single canine cerebellar cortical degeneration case leads to the identification of a disease associated SPTBN2 mutation. BMC Genet 2012; 13: 55.
12. Wohlke A, Philipp U, Bock P, Beineke A, Lichtner P, Meitinger T et al. A one base pair deletion in the canine ATP13A2 gene causes exon skipping and late-onset neuronal ceroid lipofuscinosis in the Tibetan terrier. PLoS Genet 2011; 7: e1002304.
13. Farias FH, Zeng R, Johnson GS, Shelton GD, Paquette D, O'Brien DP. A L2HGDH initiator methionine codon mutation in a Yorkshire terrier with L-2-hydroxyglutaric aciduria. BMC Vet Res 2012; 8: 124.
14. Li FY, Cuddon PA, Song J, Wood SL, Patterson JS, Shelton GD et al. Canine spongiform leukoencephalomyelopathy is associated with a missense mutation in cytochrome b. Neurobiol Dis 2006; 21: 35-42. (Pubitemid 41817303)
15. Nadon NL, Duncan ID, Hudson LD. A point mutation in the proteolipid protein gene of the 'shaking pup' interrupts oligodendrocyte development. Development 1990; 110: 529-537. (Pubitemid 20330529)
16. Abee CR (ed). Nonhuman Primates in Biomedical Research: Diseases (American College of Laboratory Animal Medicine Series), 2012, Volume 2, Elsevier: London (electronic resource).
17. Luzi P, Rafi MA, Victoria T, Baskin GB, Wenger DA. Characterization of the rhesus monkey galactocerebrosidase (GALC) cDNA and gene and identification of the mutation causing globoid cell leukodystrophy (Krabbe disease) in this primate. Genomics 1997; 42: 319-324. (Pubitemid 27263763)
18. Mellersh C, Sargan D. DNA testing in companion animals-what is it and why do it In Practice 2011; 33: 442.
19. Ellinwood NM, Vite CH, Haskins ME. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 2004; 6: 481-506. (Pubitemid 40228065)
20. Haskins M. Gene therapy for lysosomal storage diseases (LSDs) in large animal models. ILAR J 2009; 50: 112-121.
21. Davis KA, Sturges BK, Vite CH, Ruedebusch V, Worrell G, Gardner AB et al. A novel implanted device to wirelessly record and analyze continuous intracranial canine EEG. Epilepsy Res 2011; 96: 116-122.
22. Bosch MN, Pugliese M, Gimeno-Bayon J, Rodriguez MJ, Mahy N. Dogs with cognitive dysfunction syndrome: a natural model of Alzheimer's disease. Curr Alzheimer Res 2012; 9: 298-314.
23. Kyostila K, Cizinauskas S, Seppala EH, Suhonen E, Jeserevics J, Sukura A et al. A SEL1L mutation links a canine progressive early-onset cerebellar ataxia to the endoplasmic reticulum-associated protein degradation (ERAD) machinery. PLoS Genet 8: e1002759.
24. de Lahunta A. Abiotrophy in domestic animals: a review. Can J Vet Res 1990; 54: 65-76.
25. Fyfe JC, Al-Tamimi RA, Liu J, Schaffer AA, Agarwala R, Henthorn PS. A novel mitofusin 2 mutation causes canine fetal-onset neuroaxonal dystrophy. Neurogenet 2011; 12: 223-232.
26. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50 (2 Suppl 1): S16-S22. (Pubitemid 28100862)
27. Dowling AL, Head E. Antioxidants in the canine model of human aging. Biochim Biophys Acta 2012; 1822: 685-689.
28. Moreno-Gonzalez I, Soto C. Natural animal models of neurodegenerative protein misfolding diseases. Curr Pharm Des 2012; 18: 1148-1158.
29. Summers BA, Cummings JF, DeLahunta A. Veterinary Neuropathology. Mosby: St. Louis, MO, USA, 1995, xiii, pp 527.
30. deLahunta A, Glass EN. Veterinary Neuroanatomy and Clinical Neurology. Saunders Elsevier: St. Louis, MO, USA, 2009.
31. Trojanowski JQ, Hendricks JC, Jedrziewski K, Johnson FB, Michel KE, Hess RS et al. Exploring human/animal intersections: converging lines of evidence in comparative models of aging. Alzheimers Dement 2008; 4: 1-5.
32. Alisky JM, Hughes SM, Sauter SL, Jolly D, Dubensky Jr TW, Staber PD et al. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport 2000; 11: 2669-2673.
33. Vite CH, Passini MA, Haskins ME, Wolfe JH. Adeno-associated virus vectormediated transduction in the cat brain. Gene Ther 2003; 10: 1874-1881. (Pubitemid 37258634)
34. Bevan AK, Duque S, Foust KD, Morales PR, Braun L, Schmelzer L et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 2011; 19: 1971-1980.
35. Cearley CN, Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 2006; 13: 528-537. (Pubitemid 43257620)
36. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19: 1058-1069.
37. Klein RL, Dayton RD, Tatom JB, Henderson KM, Henning PP. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol Ther 2008; 16: 89-96.
38. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59-65.
39. Dayton RD, Wang DB, Klein RL. The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther 12: 757-766.
40. Haskins ME, Giger U, Patterson DF. Animal models of lysosomal storage diseases: their development and clinical relevance. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry Disease: Perspectives from 5 years of Fabry Outcome Survey. Oxford PharmaGenesis: Oxford, UK, 2006.
41. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791-801. (Pubitemid 34033377)
42. Cearley CN, Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 2007; 27: 9928-9940. (Pubitemid 47404014)
43. Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 2007; 15: 481-491.
44. Hennig AK, Levy B, Ogilvie JM, Vogler CA, Galvin N, Bassnett S et al. Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J Neurosci 2003; 23: 3302-3307. (Pubitemid 36531971)
45. Ciron C, Cressant A, Roux F, Raoul S, Cherel Y, Hantraye P et al. Human alphaiduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution. Hum Gene Ther 2009; 20: 350-360.
46. Bu J, Ashe KM, Bringas J, Marshall J, Dodge JC, Cabrera-Salazar MA et al. Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A. Mol Ther 2012; 20: 1893-1901.
47. Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, Jens JK et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 2011; 19: 251-259.
48. Ciron C, Desmaris N, Colle MA, Raoul S, Joussemet B, Verot L et al. Gene therapy of the brain in the dog model of Hurler's syndrome. Ann Neurol 2006; 60: 204-213. (Pubitemid 44182395)
49. Masamizu Y, Okada T, Kawasaki K, Ishibashi H, Yuasa S, Takeda S et al. Local and retrograde gene transfer into primate neuronal pathways via adeno-associated virus serotype 8 and 9. Neuroscience 2011; 193: 249-258.
50. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, Bringas JR et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 2012; 23: 382-389.
51. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 2013; 20: 450-459.
52. Haurigot V, Marco S, Ribera A, Garcia M, Ruzo A, Villacampa P et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 2013; 123: 3254-3271.
53. Rosenberg JB, Sondhi D, Rubin DG, Monette S, Chen A, Sevin C et al. CNS administration of an AAVrh.10 gene transfer vector expressing the human ARSA cDNA to nonhuman primates provides widespread activity across the CNS. Mol Ther 2013; 21(suppl): S225.
54. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005; 12: 1072-1082. (Pubitemid 41723041)
55. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009; 374: 1597-1605.
56. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009; 20: 999-1004.
57. Lock M, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther 2010; 21: 1259-1271.